# The Lancet Rheumatology

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/the-lancet-rheumatology/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 2665-9913 |
| ISSNs | 2665-9913 |
| OpenAlex ID | https://openalex.org/S4210233594 |
| Publisher | Elsevier BV |

## Journal papers

Showing 12 of 18.

- [Anakinra for severe forms of COVID-19: a cohort study](https://scholariq.org/papers/anakinra-for-severe-forms-of-covid-19-a-cohort-study/)
- [Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021](https://scholariq.org/papers/global-regional-and-national-burden-of-rheumatoid-arthritis-1990-2020-and/)
- [Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine](https://scholariq.org/papers/central-sensitisation-in-chronic-pain-conditions-latest-discoveries-and-their/)
- [COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study](https://scholariq.org/papers/covid-19-outcomes-in-patients-with-inflammatory-rheumatic-and-musculoskeletal/)
- [Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study](https://scholariq.org/papers/lupus-low-disease-activity-state-as-a-treatment-endpoint-for-systemic-lupus/)
- [Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis](https://scholariq.org/papers/effect-of-anakinra-on-mortality-in-patients-with-covid-19-a-systematic-review/)
- [Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study](https://scholariq.org/papers/risk-of-hydroxychloroquine-alone-and-in-combination-with-azithromycin-in-the/)
- [COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study](https://scholariq.org/papers/covid-19-in-patients-with-rheumatic-diseases-in-northern-italy-a-single-centre/)
- [COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study](https://scholariq.org/papers/covid-19-in-patients-with-rheumatic-disease-in-hubei-province-china-a/)
- [Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study](https://scholariq.org/papers/factors-associated-with-damage-accrual-in-patients-with-systemic-lupus-2/)
- [Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)](https://scholariq.org/papers/abatacept-treatment-for-patients-with-early-active-primary-sjogren-s-syndrome-a/)
- [Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study](https://scholariq.org/papers/lupus-low-disease-activity-state-and-remission-and-risk-of-mortality-in-patients/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.